Atezolizumab plus FLOT regimen beneficial for resectable esophagogastric adenocarcinoma
The effects of atezolizumab combined with a chemotherapy regimen were beneficial in terms of pathologic outcome compared with the chemotherapy regimen alone for patients with resectable esophagogastric adenocarcinoma.
The results of the DANTE phase 2b trial examining the FLOT (docetaxel, oxaliplatin, leucovorin and 5-fluorouracil) regimen were presented at ASCO Annual Meeting. "Perioperative FLOT plus atezolizumab is feasible and safe," Salah-Eddin Al-Batran, MD, lead author of the study, said during an oral abstract session.
The multicenter, investigator-initiated, phase 2b trial evaluated 295 patients randomized into two arms: one receiving only FLOT chemotherapy and one receiving the same regimen of chemotherapy plus atezolizumab. The atezolizumab arm received 840 mg every other week followed by eight cycles of monotherapy at 1,200 mg once every 3 weeks.
"The addition of atezolizumab improved downstaging, with more patients being in favorable postoperative T and N categories," Al-Batran, director of Institute of Clinical Cancer Research and director of GI Oncology at Krankenhaus Nordwest-University Cancer Center in Frankfurt, Germany, said.
Patients in both arms completed preoperative FLOT cycles at a rate of 93% and postoperative cycles at 43%, according to researchers.
"It also showed the beneficial effects on path regression that seemed to be more pronounced with higher PD-L1 expression and in patients with MSI-high status,” Al-Batran said. “The analysis justifies the transition into a phase 3 trial.”
Collapse
Read more about